Navigation Links
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:1/3/2012

SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on December 22, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 39,625 shares of common stock to 4 new employees.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Each stock option has an exercise price per share equal to $12.24 the fair market value on December 30, 2011, and vests over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. Each stock option was effective as of December 30, 2011, and also has a ten year term and is subject to the terms and conditions of the Company's 2006 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.

The stock options were granted as inducements material to the new employees entering into employment with Optimer in accordance with NASDAQ Listing Rule 5635(c)(4).

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin i
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
2. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
3. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
4. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
5. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
6. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
8. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
9. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
10. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... IRVINE, Calif. , Oct 22, 2014 ... Irvine, California , announced the receipt ... Small Business Innovation Research award (SBIR) from the National Institute of ... will fund the development of a Pan-HIV Protein Microarray ... the HIV-1 and HIV-2 subtypes and aid in the ...
(Date:10/22/2014)... Oct. 22, 2014  Paper Pak Industries, a ... APLS ® Body Guard Bio, a disposable, ... of bacteria and virus while protecting service providers ... Bio features a rugged, external nylon shell, watertight ... a leak-proof inner chamber that contains contaminated and ...
(Date:10/22/2014)... , Oct. 22, 2014  With a ... animal health medications, a Global Pharmaceutical and Biotech ... serialization technology and turnkey solution to protect their ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... that was serialized and aggregated by the Xyntek ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... 30 Shire plc (LSE: SHP, ... announced findings at a major medical meeting from a Phase ... Daytrana ® (methylphenidate transdermal system) in adolescents aged 13 ... ). In addition, data regarding the pharmacokinetic profile ...
... , SAN DIEGO, Oct. 30 Gen-Probe Incorporated (Nasdaq: ... the Oppenheimer 20th Annual Healthcare Conference in New York on ... at the Lazard Capital Markets 6th Annual Healthcare Conference in ... Eastern time. The presentations are scheduled to be webcast ...
Cached Medicine Technology:Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 2Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 3Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 4Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 5Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 6Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 7Gen-Probe to Webcast Two Upcoming Investor Presentations 2
(Date:10/22/2014)... 22, 2014 Isabel Healthcare ... Health Professions (ASAHP) Conference on October 22-24 in Las ... participate in a panel discussion on Technology in Health ... Healthcare provides a diagnostic decision support tool and clinical ... skills of students and clinical learners. The Isabel tools ...
(Date:10/22/2014)... 2014 The Louis W. ... dedicated to distribute health information technology innovation to ... announced the development of six key guiding principles ... receiving healthcare. These are an expansion of the ... care that is respectful of and responsive to ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a ... of bacterial infections, microbial biofilms, and chronic wounds, announced ... of directors. , Dr. Sinskey is ... Massachusetts Institute of Technology, or MIT. He has been ... Sinskey also holds positions as Co-Director of the Malaysia-MIT ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. ... in vitro fertilization (IVF) -- the incubation of embryos in ... device inside the vagina, new research suggests. Scientists from ... an INVOcell, might sharply cut costs for pricey IVF procedures ... accessible to those who don,t live near big-city assisted reproduction ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... Dendreon Corporation (Nasdaq:,DNDN) will release its third quarter financial ... conference call at 1:30,p.m. PT; 4:30 p.m. ET to review ... discussion may be obtained as follows: Time: ... November 15, 2007 Dial-in: ...
... 17th U.S. Surgeon General Richard H. Carmona Joins ... Says Report Findings May Open,Doors to Positive Change, ... and Prevent (STOP) Obesity Alliance today received a ... obesity in America:,unrealistic definitions of success, negative perceptions ...
... ARLINGTON, Va., Nov. 2 FBR Capital Markets,Corporation ... that,Christopher Warren has joined FBR Capital Markets as a ... group and will,focus on the medical device sector. ... research, and we,value the disciplined, rigorous method he,s developed ...
... dexamethasone contributes to a relentless fatigue and poor quality ... leukemia (ALL), according to a new study from St. ... could improve the quality of life for these children ... or eliminate these side effects. , The St. ...
... ... Options, WASHINGTON, Nov. 2 Today, the Society ... interventional cardiology, announced the,launch of Seconds Count, a patient ... authoritative resource about cardiovascular disease and,treatment. The program will ...
... Duane Reade Holdings, Inc. today,announced that on Thursday, November ... results before the open of the market. In ... conference,call on Thursday, November 8, 2007 at 10:00 a.m. ... Officer, and John Henry,Senior Vice President and Chief Financial ...
Cached Medicine News:Health News:-Dendreon to Hold Conference Call on Thursday, November 15, 2007 at 4:30 PM ET- 2Health News:New Academic Analysis Identifies Three Barriers to Achieving Healthy and Achievable Policies to Combat Obesity in America 2Health News:New Academic Analysis Identifies Three Barriers to Achieving Healthy and Achievable Policies to Combat Obesity in America 3Health News:FBR Capital Markets Hires Senior Healthcare Analyst 2Health News:St. Jude finds anti-leukemia drug increases patient fatigue 2Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 2Health News:New Web Site Helps Patients Navigate Heart Disease Treatment Options 3
Provides extended cold therapy to the shoulder area for acute, chronic, or post-surgical applications. The DuraKold products can help reduce pain, edema, and speed recovery....
Provides continuous cold therapy to the knee area for acute, chronic, or post-surgical applications. Cryotherapy can reduce pain, swelling and facilitate faster rehabilitation....
... Halo™ was designed in 1988 as an attachment ... patient, it greatly restricts rotation of the cervical ... Halo can be removed while allowing the Collar ... used in conjunction with the Philadelphia Stabilizer attachment., ...
... cold therapy Gel Pad. Our Gel Pad helps ... to reduce swelling and /or hot therapy to ... order hot and cold therapy gel pad, place ... suspenders can be added to each support upon ...
Medicine Products: